Ontario Court of Appeal denies generic pharmaceutical company's claim for innovator's profits

1 minute read
01 May 2015

Apotex Inc. v. Eli Lilly and Company, 2015 ONCA 305

On May 5, 2015, the Ontario Court of Appeal denied a generic pharmaceutical company’s claim for unjust enrichment. This was an appeal by Apotex Inc. from a Divisional Court decision to grant a motion by Eli Lilly and Company and Eli Lilly Canada Inc.’s (“Lilly”) to strike Apotex’s claim for unjust enrichment from the sales of a drug used to treat Attention Deficit Hyperactivity Disorder.

In a unanimous judgment, the Court dismissed the appeal, finding that Apotex’s claim did not satisfy the Supreme Court of Canada’s test for unjust enrichment because there was no deprivation of Apotex that corresponded to an enrichment of Lilly.

Patrick Smith and Todd Burke of Gowlings appeared for Lilly in these proceedings.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.